Osvaldas Vainauskas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Osvaldas Vainauskas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Mosca
Department of Medical Oncology, Maggiore della Carità University Hospital, Novara, Italy
7 shared publications - Anna Wingate
University College London Cancer Institute, London, United Kingdom
7 shared publications - Chiara Casadei
Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola (FC), Italy
7 shared publications - Cristian Lolli
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
7 shared publications - Daniel Wetterskog
University College London Cancer Institute, London, UK
7 shared publications - Emilio Francesco Giunta
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
7 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1 from Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer
Supplementary Tables and Representativeness of study participants
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1 from Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer
Supplementary Tables and Representativeness of study participants
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 4985-4995
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer
Purpose: Taxanes are life-prolonging treatments for patients with advanced prostate cancer. However, treatment resistance and lethal disease invariably develop. Here we used liquid biopsies to identify and characterize resistance to cabazitaxel. Experimental Design: We analyzed serial plasma from patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in a prospective biomarker study (NCT03381326, N = 97). ctDNA was studied using a bespoke, targeted genomic test (PCF_SELECT). Clinical and molecular variables were evaluated for associations with overall survival (OS) and radiographic progression-free survival (rPFS). Results: Patients categorized by median ctDNA fraction had progressively worse survival for ctDNA-negative versus -low versus -high patients (median OS: 26.8, 12.4, and 8.2 months; median rPFS: 8.0, 5.3, and 3.1 months). A ctDNA fraction increase at cycle 3 compared with patients who remained ctDNA negative associated with shorter OS [median, 7.5 vs. 29.9 months; HR, 4.60 (95% confidence interval, 2.06–10.28), P < 0.0001] and rPFS [median, 2.6 vs. 8.2 months; HR, 3.73 (95% confidence interval, 1.75–7.93), P < 0.0001]. Plasma DNA collected at progression on an androgen receptor pathway inhibitor was enriched for alterations in the androgen receptor gene, whereas after a taxane (docetaxel before cabazitaxel or after cabazitaxel), there was enrichment of copy-number gains of genes sited on chromosome 3 (ATR, PIK3CB, MLH1, and FANCD2) or involved in cell cycle regulation, including mutually exclusive alterations in CCND1 and CDKN1B. Conclusions: Sequential liquid biopsy identifies ctDNA features associated with treatment benefit in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. There was overlap of gene alterations selected for at progression on docetaxel or cabazitaxel, in part explaining cross-resistance.
- 13 October 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (23) , 4985-4995
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer
Purpose: Taxanes are life-prolonging treatments for patients with advanced prostate cancer. However, treatment resistance and lethal disease invariably develop. Here we used liquid biopsies to identify and characterize resistance to cabazitaxel. Experimental Design: We analyzed serial plasma from patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in a prospective biomarker study (NCT03381326, N = 97). ctDNA was studied using a bespoke, targeted genomic test (PCF_SELECT). Clinical and molecular variables were evaluated for associations with overall survival (OS) and radiographic progression-free survival (rPFS). Results: Patients categorized by median ctDNA fraction had progressively worse survival for ctDNA-negative versus -low versus -high patients (median OS: 26.8, 12.4, and 8.2 months; median rPFS: 8.0, 5.3, and 3.1 months). A ctDNA fraction increase at cycle 3 compared with patients who remained ctDNA negative associated with shorter OS [median, 7.5 vs. 29.9 months; HR, 4.60 (95% confidence interval, 2.06–10.28), P < 0.0001] and rPFS [median, 2.6 vs. 8.2 months; HR, 3.73 (95% confidence interval, 1.75–7.93), P < 0.0001]. Plasma DNA collected at progression on an androgen receptor pathway inhibitor was enriched for alterations in the androgen receptor gene, whereas after a taxane (docetaxel before cabazitaxel or after cabazitaxel), there was enrichment of copy-number gains of genes sited on chromosome 3 (ATR, PIK3CB, MLH1, and FANCD2) or involved in cell cycle regulation, including mutually exclusive alterations in CCND1 and CDKN1B. Conclusions: Sequential liquid biopsy identifies ctDNA features associated with treatment benefit in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. There was overlap of gene alterations selected for at progression on docetaxel or cabazitaxel, in part explaining cross-resistance.